免疫调节分子 PD-L1 和 PD-1 在口腔癌及癌前病变中的表达：一项日本患者的队列研究。
Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients.
机构信息
Division of Oral and Maxillofacial Surgery, Department of Oral Medicine and Surgery, Tohoku University Graduate School of Dentistry (Head of the institution: Tetsu Takahashi), 4-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
Department of Pathology, Miyagi Cancer Center (Head of the institution: Ikuro Sato), 47-1 Nodayama, Medeshima-Shiode, Natori, Miyagi 981-1293, Japan.
出版信息
J Craniomaxillofac Surg. 2019 Jan;47(1):33-40. doi: 10.1016/j.jcms.2017.04.013. Epub 2017 May 10.
OBJECTIVE
An association of the programmed cell death-1 (PD-1) and its ligand PD-L1 with various types of malignant tumors has been established. This study aimed to investigate the role of the PD-L1/PD-1 pathway in oral squamous cell carcinoma (OSCC) and oral epithelial precursor lesions (OEPL).
MATERIALS AND METHODS
We examined 106 OSCC and 79 OEPL specimens for PD-L1 and PD-1 expression by immunohistochemistry. The results were compared with clinicopathological features of OSCC patients.
RESULTS
In OSCC and OEPL specimens, PD-L1 expression was detected predominantly in epithelial or carcinoma cells, whereas PD-1 expression was found mainly in infiltrating or stromal lymphocytes. Seventy-two OSCC (67.9%) and 21 OEPL (26.6%) specimens were positive for PD-L1, and 73 OSCC (68.9%) and 23 OEPL (29.2%) specimens were positive for PD-1. PD-L1 and PD-1 expression levels were significantly different between OEPL and OSCC specimens (P < 0.001). There were significant positive correlations between PD-L1 and PD-1 expression in OEPL and OSCC specimens (P < 0.001). PD-L1 and PD-1 immunoreactivity was significantly associated with tumor size (P < 0.05). PD-L1 and PD-1 immunoreactivity in cases with advanced TNM staging was significantly higher than that in low staging cases (P < 0.01). There were significant correlations between PD-L1 and PD-1 expression in OSCC specimens and pathological variables such as stromal lymphocytic reaction (P < 0.05) and invasion depth (P < 0.01).
CONCLUSION
PD-L1 and PD-1 immunohistochemical status may be related to carcinogenesis, tumor progression, and prognosis in oral epithelial lesions. Agents targeting PD-1 and PD-L1 might be useful for OSCC treatment.
目的
已证实程序性细胞死亡-1（PD-1）及其配体 PD-L1 与多种恶性肿瘤有关。本研究旨在探讨 PD-L1/PD-1 通路在口腔鳞状细胞癌（OSCC）和口腔上皮前病变（OEPL）中的作用。
材料和方法
我们通过免疫组织化学法检测了 106 例 OSCC 和 79 例 OEPL 标本中 PD-L1 和 PD-1 的表达。并将结果与 OSCC 患者的临床病理特征进行比较。
结果
在 OSCC 和 OEPL 标本中，PD-L1 表达主要见于上皮细胞或癌细胞，而 PD-1 表达主要见于浸润或间质淋巴细胞。72 例 OSCC（67.9%）和 21 例 OEPL（26.6%）标本 PD-L1 阳性，73 例 OSCC（68.9%）和 23 例 OEPL（29.2%）标本 PD-1 阳性。OEPL 和 OSCC 标本中 PD-L1 和 PD-1 的表达水平差异有统计学意义（P<0.001）。OEPL 和 OSCC 标本中 PD-L1 和 PD-1 的表达呈显著正相关（P<0.001）。PD-L1 和 PD-1 免疫反应与肿瘤大小显著相关（P<0.05）。TNM 分期较高的病例中 PD-L1 和 PD-1 免疫反应明显高于分期较低的病例（P<0.01）。OSCC 标本中 PD-L1 和 PD-1 的表达与间质淋巴细胞反应（P<0.05）和浸润深度（P<0.01）等病理变量显著相关。
结论
PD-L1 和 PD-1 的免疫组织化学状态可能与口腔上皮病变的癌变、肿瘤进展和预后有关。针对 PD-1 和 PD-L1 的药物可能对 OSCC 的治疗有用。
Zotero 插件